04.04.25 -- The Importance Of Primary And Secondary Drying In Lyophilization

Biopharma executives Robert Discordia, CEO, Equulus Therapeutics, and Reza Oliyai, CEO, Oliyai Consulting, agree we may not have seen the last of the Act… or tariffs to compound industry challenges.

Regulatory-CMC defines Sai Prathyusha Bhamidipati’s career at Moderna. Focused on compliance in pharmaceutical production and QC, she highlights its crucial role when working with CDMOs.

Understanding the potential pitfalls and partnering with the right experts can make all the difference in overcoming the complexities of complex generic OSD development.

The development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.

Drug developers and manufacturers must address several key challenges, including formulation complexity, improving the bioavailability of poorly soluble compounds, and optimizing drug release profiles.

A healthcare manufacturer facing space constraints and regulatory pressures outsourced their stability storage needs to another company, resulting in reduced costs and focus on core competencies.

Explore a solvent-free alternative for the production of amorphous solid dispersions (ASDs) that not only improves manufacturability but also reduces the carbon footprint of ASD manufacturing.

Without clear visibility into your operations, you risk creating blind spots that could extend lead times, causing unnecessary waste and quality issues. Consider the advantages of a modern MES.

By combining deep scientific expertise with cutting-edge technology, we ensure the safety and effectiveness of each formulation through precise control of API release.

Our team of 1,000+ employees operates across two continents, seamlessly integrating drug product development, manufacturing, and clinical pharmacology expertise.

Understand how free trade zones work, and explore a flexible and cost efficient way to supply clinical trials in China and around the globe.